Research on lung cancer detection and treatment. Covers microbial predictors of immunotherapy, MRI detection, microplastics, and RAS-mutant drugs.
Researchers found that individuals exposed to wildfires within a year of lung cancer surgery had significantly lower overall survival rates compared to those not exposed. The closer the exposure occurred to the surgery, the worse the survival rate, with patients exposed 3-6 months after surgery facing a 48% decrease in survival chances.
A new study published in Radiology found that AI can use data from low-dose CT scans of the lungs to improve risk prediction for death from various causes. The study used data from over 20,000 individuals and found that body composition measurements derived from lung screening LDCT were strong predictors of mortality.
Using plasma circulating tumor DNA testing can expedite biomarker testing and time to treatment for patients with suspected advanced lung cancer. The study suggests that this approach may improve patient outcomes.
The July issue of CHEST journal features 49 articles on clinically relevant topics, including disability rights and life-sustaining treatment. The journal offers complementary web resources, such as visual abstracts, to expand the reach of its research.
A new study reveals that the cellular chaperone protein GRP78 migrates to the nucleus under stress and alters gene activities, allowing cancer cells to become more mobile and invasive. This discovery offers potential new approaches for cancer treatment, including down-regulating GRP78 activity or preventing it from binding to ID2.
A global study shows atezolizumab significantly improved overall survival and resulted in a clinically meaningful long-term survival benefit for advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy. The treatment also showed stabilised or improved health-related qualit...
A blood-based four-protein panel and personalized risk model can predict an individual's risk of dying from lung cancer, improving sensitivity and specificity compared to current guidelines. The test has the potential to save lives by determining the need for lung cancer screening on a personalized basis.
Researchers explore pyroptosis as a potential therapeutic approach for lung cancer treatment. The review highlights the dual role of pyroptosis in tumor progression and negative impact on normal cells. It suggests balancing the contradictory effects of pyroptosis to optimize clinical applications.
A study published in Radiology found that AI algorithms with high diagnostic accuracy improved radiologists' detection of lung cancers on chest X-rays. High-accuracy AI led to more frequent changes in reader determinations, suggesting increased human trust in AI.
A newly discovered radionuclide-based agent (CB-2PA-NT) has shown high tumor uptake, sustained retention, and contrast in preclinical models. Targeting neurotensin receptors, CB-2PA-NT expands precision medicine for cancer diagnosis and treatment.
Researchers developed a risk calculator using persistent homology scores from CT scans, which is the strongest predictor of overall survival among standard clinical measures. The calculator has the potential to guide clinicians in choosing treatment options and transform the way outcomes are predicted.
Researchers at MD Anderson Cancer Center have identified disparities in end-of-life immunotherapy treatment, highlighting the need for further examination to ensure quality care. A new study also reveals a novel target to improve immunotherapy responses in KRAS-mutant lung cancer and strategies to manage immune-related toxicities.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
The study found a decreasing trend in the global TBL cancer burden from 1990 to 2019, but regional variations persisted. The burden was highest in upper-middle-income countries and lowest in high-income countries.
A new study from the Van Andel Research Institute reveals that loss of two key 'protector' proteins, TET and RYBP, transforms healthy lung cells into cancerous ones through epigenetic changes. The research found that deficiency of these proteins leads to widespread aberrant methylation and malignant transformation.
The study found that lung cancer screening rates among eligible adults in Maine, Michigan, New Jersey, and Rhode Island increased in 2021 compared to 2019. Consistent with prior studies, the likelihood of lung cancer screening was higher among individuals with a primary health professional
A recent study reveals lower lung cancer screening rates among Black veterans, underscoring the need for further research into barriers to screening and evidence-based interventions. The findings suggest that demographics alone do not fully explain these disparities.
Researchers found adagrasib effective in suppressing cancer growth in both lungs and brain metastases, with a 90% intracranial disease control rate and 42% objective response rate. The median intracranial progression-free survival was 5.4 months, while the median overall survival reached 11.4 months.
The June issue of CHEST features 49 articles on clinically relevant topics, including asthma, COPD, and critical care. The journal offers web and multimedia resources to expand the reach of its research.
Researchers found a link between short telomeres in ATII cells and lung fibrosis in post-COVID-19 patients. The study revealed loss of ATII cellularity and shorter telomeres concomitant with increased fibrotic lung parenchyma remodeling.
A new study published in JNCCN found that taking alectinib, a medication for advanced lung cancer, with a full breakfast or lunch resulted in higher drug concentrations than with a low-fat breakfast. This could impact treatment efficacy and survival rates for patients.
A new study found that obesity is associated with an increased risk of certain cancers, with stronger links in female patients for gallbladder and endometrial cancer. The study also revealed differential effects between sexes on colorectal, esophageal, and liver cancer.
A new study found significant reductions in breast, colorectal and prostate cancers as well as melanoma diagnoses in Alberta during the COVID-19 pandemic. Diagnoses dropped by 43% for melanoma, 36% for colorectal and prostate, and 33% for breast cancer during the 'state of emergency' phase.
A Yale-led study found that osimertinib significantly improved rates of survival and reduced risk of recurrence in patients with non-small cell lung cancer after surgery. The trial showed a 51% reduction in mortality risk, with 88% of patients surviving at least five years.
A new observational study published in BMJ Open found that long Covid can have a devastating effect on daily lives, with fatigue impacting social activities, work, and relationships. The study's findings suggest that long Covid can leave people with worse fatigue and quality of life than some cancers.
A retrospective study found a 24% response rate to Docetaxel among patients with stage IV non-small cell lung cancer who experienced progression on immunotherapy. The median progression-free survival was 3 months, suggesting chemotherapy may still play an important role in treatment after immunotherapy failure.
The study, published in JAMA Oncology, found that the percentage of cancer survivors reporting functional limitations has more than doubled over the past 20 years. The adjusted prevalence of functional limitation was highest among pancreatic and lung cancer survivors, while melanoma survivors had the lowest rate.
A retrospective cohort study suggests that stopping immunotherapy treatment at two years is a valid strategy without compromising overall survival. The researchers analyzed data from 1,091 patients and found similar overall survival probabilities between those who stopped treatment and continued it indefinitely.
A study published in JAMA Oncology suggests that stopping immunotherapy after two years for patients with advanced non–small cell lung cancer who remain responsive may be a reasonable strategy, providing sustained clinical benefit. The findings provide reassurance for patients and their healthcare providers.
Researchers at UCLA Health highlight the impact of test results on lung cancer screening adherence and the potential unnecessary use of axillary ultrasound in breast cancer diagnostics. Meanwhile, a new AI system helps check endotracheal tube placement with high accuracy and user satisfaction.
A study by University of Technology Sydney found that plants can remove 97% of toxic compounds, including cancer-causing pollutants, from indoor air in just eight hours. This breakthrough discovery highlights the critical role played by indoor plants and green walls in improving air quality.
A new study published in the Journal of the American College of Surgeons predicts a significant increase in cancer cases due to COVID-19 screening delays, with lung, breast, and colorectal cancers most affected. The study found that missed diagnoses during the pandemic may lead to delays in treatment and upstaging of disease.
Researchers have studied targeting telomeres as a potential therapeutic strategy for non-small cell lung cancer. Telomere dysfunction and telomerase deficiency slowed tumor progression, increasing vulnerability to DNA damage and immune system response.
A study found that over half of English NSCLC patients living in low-socio-economic areas did not receive new anti-cancer therapies, despite having access to free treatment through the National Health Service. The researchers examined data from 90,785 patients diagnosed between 2012 and 2017.
Researchers from China explore the mechanisms of action and clinical data of bispecific antibodies, which have shown promise in increasing cytotoxicity against cancerous cells and enhancing immune response towards tumor clearance. Several bsAbs are being evaluated in phase I-III clinical trials for lung cancer treatment.
Researchers discovered that air pollution particles trigger autophagy, a cellular defense process, which has an upper threshold and may reduce its effectiveness against other threats. This finding provides new insights into the link between air pollution and lung disease.
The May issue of the CHEST journal features cutting-edge research on pulmonary, critical care, and sleep medicine. The journal also highlights awareness for cystic fibrosis, a once-fatal childhood condition now affecting adults.
Researchers at USC Norris Comprehensive Cancer Center have identified a biomarker, CX3CR1, that can predict which patients with non-small cell lung cancer will respond well to chemoimmunotherapy. Elevated levels of the biomarker in T-cells after six to nine weeks of treatment indicate long-term benefits from the combination therapy.
Scientists have identified a specific gene mutation that triggers an inflammatory cascade, driving the development of treatment-resistant cancers. The study reveals a molecular circuitry by which mutations in the STK11 gene cause inflammation to spiral out of control.
Overweight and obesity in early adulthood are associated with increased risks of colorectal cancer and non-colorectal gastrointestinal cancers. The study highlights the need for further exploration into the mechanisms driving these associations.
Researchers developed a predictive model to identify tumor biomarkers of cachexia in lung cancer patients. The study used machine learning to build a muscle loss prediction model based on muscularity, clinical data, and the transcriptional profile from the tumor microenvironment.
A new study by Brown researchers found that 33.8% of patients with low-dose computed tomography (LDCT) screening had significant incidental findings, many of which were clinically important. The study suggests that standardizing reporting of these findings could improve patient care and reduce unnecessary medical interventions.
A new study reveals a shared molecular response to nanoparticles, linking immune activation and particulate matter exposure. The findings propose a solution to the 'one-chemical-one-signature' problem in chemical safety assessment.
Researchers have developed a new immunotherapy targeting tumour macrophages, which are immunosuppressive cells that weaken the immune system. The treatment, RImAb, reduces tumour growth and modifies the tumour microenvironment, offering potential for a new line of treatment for lung cancer patients.
A recent clinical trial showed that cemiplimab plus platinum chemotherapy can prolong survival in patients with advanced lung cancer, improving their quality of life. The treatment also reduced symptoms such as pain and cough, and delayed clinically meaningful deterioration.
Quitting smoking early after a lung cancer diagnosis was associated with lower mortality rates. Detailed smoking history collection can improve lung cancer prognosis and treatment selection. The study's findings suggest that smoking cessation timing may impact overall survival, particularly at different clinical stages.
A new study found that quitting smoking before a lung cancer diagnosis is associated with higher survival rates. Former smokers who stopped smoking years before their diagnosis had significantly longer survival than current and former smokers diagnosed with non-small cell lung cancer.
Researchers found that spinal cord stimulation reduced pain response in rats with human lung cancer tissue without compromising paclitaxel effectiveness. The study also showed SCS improved antitumor efficacy of paclitaxel, providing evidence for its potential as a companion treatment.
The guideline provides guidance on definitive local therapy options for non-small cell lung cancer with limited extracranial metastases. It emphasizes the need for a patient-centered, multidisciplinary approach to treatment decisions.
Researchers at Mount Sinai have discovered a new therapeutic approach to treating non-small-cell lung cancer by inhibiting immune system molecule TREM2 and enhancing natural killer cells. The strategy, which involves blocking TREM2 activity using an antibody, has been shown to significantly reduce lung tumor growth in mice.
Researchers found that smokers' lungs have a different inflammatory environment, leading to a specific subset of T cells that evade the body's immune response. This knowledge could lead to new treatments tailored to patients based on their smoking history.
The National Cancer Centre Singapore has strengthened its position as a leader in shaping local and international clinical trials targeted at improving outcomes for Asian cancers. A pivotal phase III trial co-chaired by a NCCS clinician scientist delivered positive results, increasing recurrence-free survival of patients with hepatocel...
Researchers discuss rapamycin's potential to delay cancer onset by slowing cell proliferation and tumor progression. The mTOR pathway is involved in both cancer and aging, making rapamycin a promising chemopreventive agent.
Researchers found that remnants of ancient retroviruses in the human genome can be targeted by antibodies to improve lung cancer treatment. The study suggests that boosting antibody responses could help predict patient response to immunotherapy and lead to improved outcomes.
Tumors with low PD-L1 levels use genetic strategies like MYC activation to avoid immune attack, but this can be predicted by monitoring for MYC status. The study's findings could lead to new clinical trials assessing MYC status as a marker for selecting patients for immunotherapy.
The S2302 Pragmatica-Lung trial is designed to be inclusive and easy to conduct, with few limits on eligibility. The study aims to answer whether a combination of ramucirumab and pembrolizumab helps patients with stage 4 non-small cell lung cancer live longer than usual treatments.
Enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body. The drug targets B7-H3 protein overexpressed on prostate cancer cells, blocking immune system inhibition and triggering tumor cell destruction by activating immune cells.
A team of scientists from City University of Hong Kong and HKUST discovered novel, tridimensional compounds with high anticancer activity and low toxicity. These compounds can overcome drug resistance in cancer cells by inducing a different cell death pathway.
The LSU Health New Orleans Louisiana Tumor Registry released the sixth report of statewide cancer incidence rates by census tract, finding that 81% of tracts met criteria for all cancers combined. Census tracts with statistically higher incidence rates were found in parishes including Orleans, Lafourche, and St. Bernard.
Researchers found that neutrophils can be pro- or anti-tumour depending on their surface markers, and those fighting tumours share cytotoxic power with neutrophils in bacterial infections. Blocking these anti-tumour neutrophils eliminates treatment benefits.